Woxsen & SixS Collaborate to Launch India's First Brain Training Lab for Athletes
Pioneering Sports Science Meets Education in a Groundbreaking Initiative
HYDERABAD, India, May 3, 2025 /PRNewswire/ -- Woxsen University has taken a pioneering step in Indian sports development with the launch of the Woxsen Sports Academy in collaboration with SixS Sports & Business Solutions Pvt Ltd., unveiling the country's first-ever Brain Training Lab for Athletes. The event brought together some of the biggest names in Indian sports and academia, setting a new benchmark in holistic athlete development.
Sports Science Meets Performance: Launch of Brain Training Lab and Biomechanics Tech
At the heart of this revolutionary initiative lies the Brain Training Lab, an innovation that integrates neuroscience and cognitive training with traditional sports performance. Designed to improve focus, reaction time, and decision-making, the lab addresses critical mental aspects of elite athletic performance.
Expanding on this, Woxsen Sports Academy has also introduced a State-of-the-Art Sports Science Centre, featuring cutting-edge Sports Biomechanics technologies:
Motion Capture System by Xsens: Captures precise 3D human motion in real time, from subtle muscle twitches to dynamic full-body movements. It ensures mobile and stable performance analysis, even in field settings.
Smart Plantar Pressure Sensor Insoles by Moticon: Offers lab-level gait and foot pressure analysis within the athlete's shoe, eliminating lab constraints.
Surface Electromyography (EMG) by Delsys: Measures muscle activation during performance and rehabilitation, providing insight into muscle behavior in varied conditions.
These technologies are instrumental in optimizing an athlete's biomechanics, technical skill, and physical conditioning.
Anju Bobby George, World Athletics Medallist & Olympian, remarked, "India's first world medal to our country — we are giving an opportunity to each one of them. They can choose between sports and education. ABF got another world medal in the junior category. This is a unique opportunity — the first time I am coming out of my academy to create a new opportunity for athletes and kids. We bring their kids to sports and still help them with their academics. Thank you to all the stakeholders — hope this brings something new for this country."
Pullela Gopichand, All England Champion & Founder of Gopichand Academy, said, "I think for me it is a great collaboration to have. Congratulations to Anthony and the idea — nobody better than Woxsen and Raul to understand this. It means a lot to me — it is not very easy for people to understand sports until you have an entire cycle of champions and failures. My students who play and do not succeed need a backup plan. Either people take the complete education route — good at cracking exams but not cracking life — or even when people succeed only in sports, how many can have a good life and manage something in sports? We need mentorship at every level — together we are addressing that today. Hopefully in the years to come, this will become a game changer for the country. Every sportsperson who spends their time playing will have the same mindset."
MSK Prasad, Former Indian Cricketer & Chief Selector, stated, "Honoured to be a part of a collaborative initiative. Sports is not just about physical aptitude, but an attitude — a fight within oneself. Going forward, we will talk about physical literacy. A combination of education and sports will definitely help."
Dr. Raul V. Rodriguez, Vice President, Woxsen University, stated, "The launch of the Brain Training Lab is a significant milestone for Woxsen and Indian sports. Through this collaboration with SixS, we are creating a forward-thinking ecosystem that nurtures the mind and body of athletes. Our goal is to provide Indian athletes with the tools, technology, and education needed to compete on the global stage. In fact, our School of Business was ranked #27 in Asia-Pacific in the QS Executive MBA Rankings. We received this recognition just day before yesterday, further affirming our academic excellence and global relevance."
Antony Chacko, CEO, SixS Sports, added, "SixS is a well-recognised sports sciences company. Children are not enjoying due to competition. The key is balance between education, health and mental stress. Sharing the same vision with MSK Prasad, Anil Nayyar, Anju Bobby George, and Pullela Gopichand, we are coming together for a common cause and revolutionising Indian sport for children, ensuring they enjoy the best education, better mental health, and are stress-free. We will produce Olympic champions."
The Woxsen-SixS partnership signals a new era of athlete development, combining education, biomechanics, mental training, and elite mentorship. With India's largest sports infrastructure, advanced technologies, and international collaborations, Woxsen is redefining the future of sports in the country.
About Woxsen University, Hyderabad:
Woxsen University, located in Hyderabad, is one of the first private universities in the state of Telangana, India. Renowned for its 200-acre state-of-the-art campus and infrastructure, Woxsen University offers new-age, disruptive programs in the fields of Business, Technology, Arts & Design, Architecture, Law, and Liberal Arts & Humanities. Woxsen also houses Asia's largest Sports Infrastructure, spread over 60 acres. With 170+ Global Partner Universities and a strong industry connect, Woxsen is recognized as one of the top universities for Academic Excellence and Global Edge. Woxsen has also secured the QS Business Masters World Ranking 2025, Rank #9 All India, Top 100 B-Schools by Times B-School Ranking 2025, Rank #6, Asia Pacific, Bloomberg Best B-School, and features in India's Best B-Schools beyond IIMs by Dalal Street Investment Journal 2025, in 4th consecutive year. Woxsen is ranked as one of the Top Professional Colleges in India by Outlook I-CARE for its undergraduate programs, securing All India Rank 12 among the Top 130 BBA Private Institutes, All India Rank 20 among the Top 160 B.Tech Private Institutes, All India Rank 3 among the Top 25 Design Private Institutes, and All India Rank 3 among the Top 30 B.Arch Private Institutes.
Photo: https://mma.prnewswire.com/media/2678636/WOXSEN_Brain_Training_Lab.jpgLogo: https://mma.prnewswire.com/media/1771070/5299336/Woxsen_University_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/woxsen--sixs-collaborate-to-launch-indias-first-brain-training-lab-for-athletes-302445079.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy
HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery of novel and precise Cas nucleases and the development of safe and efficient cargo delivery platforms, today announced a key milestone in the development of its pipeline: First patient has been dosed in an investigator-initiated trial (IIT) of GEB-101, the Company's leading in vivo genome editing program for TGFBI corneal dystrophy. The ongoing IIT is in collaboration with Prof Xingtao ZHOU, MD, PhD, Professor and President, and his team at the Eye & ENT Hospital of Fudan University in Shanghai, China. GEB-101 is a wholly owned program of GenEditBio. Preclinical assessment in non-human primates demonstrated that GEB-101 was well-tolerated after local intrastromal injection and had high safety profile with virtually undetectable off-target effect ( The preclinical research recently received the Excellence in Research Award at the 28th Annual Meeting of the American Society of Gene and Cell Therapy in May 2025 ( The IIT of GEB-101 is an open-label and dose-escalation clinical study to investigate the tolerability of GEB-101 when combined with standard treatment phototherapeutic keratectomy in adults with corneal dystrophy. The first patient, who received GEB-101 in May 2025, has been discharged from the collaborating hospital with no observable adverse event. This trial marks the world's first clinical study of an in vivo CRISPR-Cas ribonucleoprotein (RNP)-based genome editing investigational therapy for TGFBI corneal dystrophy. "Today, on National Sight Day, we are proud and honored to announce that we have initiated the world's first clinical study of an in vivo genome editing investigational therapy for corneal dystrophy. This key milestone represents years of effort in technology platform development and dedication from our world-class research team and clinical partners," said Zongli ZHENG, PhD, Chairman and Co-Founder of GenEditBio, "We stand at the frontier of a new era and recognize the transformative potential of this moment is not just for the Company but for the entire field of genetic medicine because the technology has the potential to extend far beyond corneal dystrophy. Our company is committed to developing fundamentally safe, efficacious and affordable in vivo genome editing therapies for genetic diseases with unmet medical needs". "This investigator-initiated trial marks a defining moment for our award-winning research team and clinical partners. Remarkably, in just one year since initiating our proof-of-concept and preclinical studies, we have successfully integrated our genome editing and delivery technologies to advance this pipeline program from the laboratory to clinical stage, showcasing our competence and dedication to rapidly translate basic research into clinical program to ultimately benefit patients," said Tian ZHU, PhD, CEO and Co-Founder of GenEditBio, "We also express our deepest gratitude to the participant who volunteers in this early stage trial to support medical innovation. As clinical data accumulate, we are positive that GEB-101 has the potential to become a new treatment option for patients with corneal dystrophy". About TGFBI Corneal Dystrophy TGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in abnormal protein buildup in the stromal layer of cornea. Symptoms include photophobia, gradual vision loss and recurrent corneal erosions. Current treatment options include phototherapeutic keratectomy and corneal transplantation. These procedures, however, have known limitations such as recurrence and carry risks of sight-threatening complications, underscoring the need for novel therapies. About GEB-101 GEB-101, a wholly owned program of GenEditBio, is a genome editing drug candidate designed as a once-and-done treatment for TGFBI corneal dystrophy. GEB-101 is based on the CRISPR-Cas genome editing technology that targets a particular locus in the mutated TGFBI gene. GEB-101 is encapsulated in the form of RNP in engineered protein delivery vehicle (PDV), a proprietary in vivo delivery system developed by GenEditBio. GEB-101 is to be administered by intrastromal injection and is being investigated for tolerability in the IIT. About GenEditBio Established in 2021 and headquartered in Hong Kong, China, GenEditBio is a gene therapy start-up company with an overarching strategic goal of providing potentially curative, once-and-done and programmable in vivo genome editing-based therapeutic solutions (dubbed "DNA surgery") with high safety profile, unmatched precision, and affordable access for genetic diseases with unmet needs. The Company's core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing lipid nanoparticle (LNP) and engineered protein delivery vehicle (PDV). We have research laboratories and supporting offices in Hong Kong, Beijing, and Boston. GenEditBio is financially backed by top-tier life science investors, including Qiming Venture Partners, Fangyuan Capital, Center Biotherapeutics, Lumosa Therapeutics, HKSTP Venture Fund, and others. For more information, please visit Related Previous Press Releases GenEditBio Scientist Receives Excellence in Research Award at the 28th Annual Meeting of the American Society of Gene and Cell Therapy 2025 GenEditBio to Present Preclinical Data on its Delivery Technology Platform and Drug Pipeline at the 28th Annual Meeting of the American Society of Gene and Cell Therapy Media Contact: Investors Contact: bd@ View original content: SOURCE GenEditBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
BenQ Australia to Showcase World's First Android 15 Education Display and AI-Powered Teaching Tools at EDUtech 2025
Where Innovation Meets Wellbeing in Education: Redefining Classrooms with AI and Care-Driven Technology SYDNEY, June 6, 2025 /PRNewswire/ -- BenQ is set to lead the conversation at EDUtech 2025, unveiling the world's first Android 15 education display, alongside a portfolio of AI-driven teaching tools and health-conscious classroom technologies. Visit Booth No. 814 on 11-12 June, 2025, at International Convention Centre, Sydney, to experience how BenQ continues to push the boundaries of smart, safe, and healthy education solutions. Under the theme "AI Wow – AI that Supports", BenQ emphasises its commitment to practical innovation: supporting teachers, engaging students, and ensuring lasting value for schools. "BenQ's education technology reflects a core philosophy: to empower teachers, protect students, and deliver lasting value," said Martin Moelle, Managing Director of BenQ Australia. "The launch of the world's first Android 15 education display isn't just a milestone, it's a promise. By extending this upgrade to our existing RP04 customers, we're showing that innovation and after-sales care can go hand-in-hand. With our AI tools and ClassroomCare® features, we're not just preparing for the future, we're building it for schools, today." RP04 Sets Global Milestone with Android 15 Upgrade BenQ will begin offering Android over-the-air (OTA) upgrades for its BenQ Board Pro RP04 series, which becomes the world's first Android 15 education display. What sets this upgrade apart is that it will be rolled out to all existing RP04 customers, reinforcing BenQ's commitment to after-sales service, software longevity, and long-term value. Schools already using the RP04 can expect a major performance boost, no hardware replacement required. AI That Supports: A Human-First Approach As Australian classrooms increasingly integrate AI, BenQ stands at the forefront with a human-first approach. BenQ Boards are designed to act as intelligent teaching companions, easing the workload on educators while enhancing learning outcomes. Features include: Speech Translation – Break language barriers with instant multilingual communication, ideal for Australia's diverse classrooms. EZ Math Calculator – Convert handwritten math into editable digital content for cleaner, more organised teaching materials. AI Lens – Instantly identify plants and insects to enrich science learning and spark student curiosity. These tools are aligned with AI trends in Australian education, including a focus on equity, engagement, and instructional efficiency. With BenQ, AI is about amplifying the impact of educators and enriching the student experience through practical, accessible innovation. View original content to download multimedia: SOURCE BenQ Corporation Inicia sesión para acceder a tu portafolio
Yahoo
2 hours ago
- Yahoo
NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy
Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: "Treat the Cause, Treat Early, Treat All": — A subanalysis of the NefIgArd study demonstrates that early treatment can more effectively slow disease progression and reduce irreversible nephron loss. — A prospective study indicates that early treatment with NEFECON® in patients diagnosed within 6 months may better control inflammatory responses and delay disease progression. SHANGHAI, June 6, 2025 /PRNewswire/ -- At the 62nd European Renal Association Congress (ERA 2025), nine new studies on NEFECON® were presented, two of which demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy of "Treat the Cause, Treat Early, Treat All". The new results presented at ERA 2025 demonstrate early treatment with NEFECON® can help protect renal function and slow disease progression, leading to improved disease management and an improved quality of life for patients. "The new results have validated the significant role of NEFECON® in the early intervention of IgAN, and have fully demonstrated its key value in the strategy of 'Treat the Cause, Treat Early, Treat All'." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, "These findings further underscore its outstanding clinical advantages as a first-line cornerstone therapy for IgAN. The 'Treat Early' strategy offers more proactive treatment for IgAN patients, helping to control disease progression and better protect renal function. NEFECON® is the first and only fully approved etiological treatment for IgAN in China, the U.S., and Europe, providing patients with new hope and treatment options. "The new findings provide robust evidence for early targeted intervention. They show that NEFECON® significantly reduces proteinuria and protect kidney function across all diagnostic timelines, with the greatest improvements in eGFR observed in patients diagnosed within 0.6 years." Professor Ping Fu from West China Hospital of Sichuan University commented, " This demonstrates that early treatment can more effectively slow disease progression and reduce irreversible nephron loss. Additionally, early treatment with NEFECON® in patients diagnosed within 6 months may better control inflammatory responses and delay disease progression. The Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review) also recommends NEFECON® as the preferred treatment to reduce Gd-IgA1. These results emphasize the importance of early treatment for IgAN and provide valuable guidance for clinical practice." The new results provide a strong evidence-based support for NEFECON®'s variable effects depending on treatment timing and disease duration. In a subanalysis of the NefIgArd study[1], which assessed the renal benefits of budesonide delayed-release capsules (16 mg/day) across different diagnostic timelines, 364 primary IgAN patients were stratified into quartiles based on time since biopsy-confirmed diagnosis. Results showed that NEFECON® preserved eGFR and reduced UPCR versus placebo across all quartiles, with the most significant renal protection in recently diagnosed patients. For those diagnosed <0.6 years prior to baseline, NEFECON® increased eGFR by +6.41, +5.78, and +4.79 mL/min/1.73 m² at 9, 12, and 24 months, respectively, and reduced UPCR by 51.12% at 12 months. In a prospective study evaluating the impact of budesonide on inflammatory processes in recently diagnosed versus long-standing IgAN patients[2], eligible Caucasian adults were divided into two groups: recent diagnosis (RD, n=8, ≤6 months) and established diagnosis (OD, n=6, >6 months). The RD group showed a significant increase in CLU levels from 48.38 pg/ml at baseline (T0) to 94.92 pg/ml at 3 months (T3) (p=0.036), while no significant change was observed in the OD group. This suggests that early NEFECON® treatment may modulate the renal immune microenvironment, triggering protective protein expression (e.g., CLU) to repair damage. Moreover, eGFR in the RD group gradually improved from T0 to T10, indicating better renal preservation with early intervention. NEFECON®, as the only in-disease IgAN treatment has been included in the KDIGO 2024 Clinical Practice Guideline For The Management Of Immunoglobulin A Nephropathy (IgAN) And Immunoglobulin A Vasculitis (IgAV) (public review draft), making it the only targeted therapy endorsed by both international and Chinese guidelines. About NEFECON® NEFECON® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models. In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas Therapeutics, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON® in mainland China, Hong Kong, Macau, Taiwan (China) and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicines' territories. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at Forward-Looking Statements: This press release may contain forward-looking statements based on current expectations, involving risks and uncertainties. Actual results may differ materially due to various factors. The company undertakes no obligation to update these statements unless required by law. References: 1. Lafayette R, et al. Abstract#3251-Nefecon provides kidney benefit irrespective of time since diagnosis in patients with IgAN: a subanalysis of the NefIgArd study. Presented at ERA 2025. 2. Keskinis C, et al. Abstract#2093-Targeted-Release Budesonide (TRB) treatment may have different effects on the inflammatory process in IgAN patients with recent and old diagnosis. Presented at ERA 2025. View original content: SOURCE Everest Medicines Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
